Pharma sales fall 9% in April, first decline in 2 years | Mumbai News

MUMBAI: For the first time in almost two years, the domestic pharma retail market plunged into a negative territory with a 9% decline in April, signaling a slowdown in overall industry growth. The market last saw negative growth during May and August 2020 due to weak sales during the lockdown caused by the epidemic.
The biggest concern is that sales of chronic therapies – usually more resilient – are also sluggish, with cardiac drugs also declining by 4% per month. The negative growth is attributed to the underlying impact, said an industry expert – on the basis of higher sales of covid-related portfolios over the same period last year. In between Delta Sales of Wave, Anti-Respiratory, Painkillers, Antibiotics and Anti-Virals increased.
Significantly, excluding covid-related drugs, the market was flat in April, showing a negative growth of 0.5%, according to the latest figures from market research firm IQVIA.
Overall, the value of the pharma retail market increased by 13% to Rs. 1,44,486 crore. MAT (Moving Annual Total), or the 12-month period ending in April. For a single month, it cost about Rs. 13,502 crore.
The sluggish sales at this stage reaffirm the impact on revenue, as the industry is already facing headaches due to rising inputs, logistics costs and shutdowns and supply disruptions from China over the past few months.
Due to the absence of prescriptions and low OPD (outpatient department) visits, the market saw soft sales in most therapies, excluding most covid-related drugs during 2020. In 2021, the market slowly bounced back with nationwide lockdowns and lifting of sanctions.


Source link

Leave a Comment